Patients Call For EU-Level Differential Pricing
Executive Summary
In a “strengthened call to action” to improve access to medicines, the European Patients Forum says an EU-level reflection on differential pricing is needed and that patients should to be more central to designing R&D.
You may also be interested in...
EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.